- Home
- ZYME
ZYME
Zymeworks Inc.
as 07-14-2025 3:43pm EST
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | MIDDLETOWN |
| Market Cap: | 867.6M | IPO Year: | 2017 |
| Target Price: | $19.50 | AVG Volume (30 days): | 494.5K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.03 - $17.70 | Next Earning Date: | 07-31-2025 |
| Revenue: | $93,384,000 | Revenue Growth: | 85.05% |
| Revenue Growth (this year): | 44.71% | Revenue Growth (next year): | 34.57% |
Stock Insider Trading Activity of Zymeworks Inc. (ZYME)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | ZYME | Director10% Owner | May 15 '25 | Buy | $11.61 | 55,421 | $635,585.71 | 17,877,989 | |
| EcoR1 Capital, LLC | ZYME | Director10% Owner | Apr 16 '25 | Buy | $11.34 | 128,713 | $1,456,407.88 | 17,877,989 |
Latest Zymeworks Inc. News
ZYME Breaking Stock News: Dive into ZYME Ticker-Specific Updates for Smart Investing
Simply Wall St.
20 days ago
Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth
GlobeNewswire
a month ago
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
GlobeNewswire
2 months ago
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
GlobeNewswire
2 months ago
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
2 months ago
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
Simply Wall St.
2 months ago
Analyst Forecasts For Zymeworks Inc. (NASDAQ:ZYME) Are Surging Higher
Simply Wall St.
2 months ago
Zymeworks First Quarter 2025 Earnings: Beats Expectations
GlobeNewswire
2 months ago
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
Compare ZYME vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZYME Zymeworks Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.